Hercules Capital Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Investment Income:: $141.5 million, a record high, up 18.4% year-over-year.

Net Investment Income (NII):: $88.1 million or $0.48 per share, up 13.8% year-over-year.

Core Yield:: 12.2%, slightly down from 12.5% in the previous quarter.

Return on Equity (ROE):: 16.9%, an increase from 16.4% in Q4 2025.

Net Asset Value (NAV) per Share:: $11.90, down 1.9% from Q4 2025.

GAAP Leverage:: Increased to 115.4%, up from 104.4% in Q4 2025.

Liquidity:: Over $1 billion across the platform, with $454.5 million in the BDC.

2Strategic Updates and Business Highlights

Record Originations:: $1.81 billion in new debt and equity commitments, with gross fundings exceeding $706 million.

Portfolio Composition:: 50% in life sciences and 50% in technology, with a focus on diversification.

Credit Quality:: Stable with a weighted average internal credit rating of 2.11; only 0.9% of loans rated 4 or 5.

M&A Activity:: Four new M&A events in the portfolio, indicating strong exit opportunities.

Leadership Changes:: Seth Meyer transitioning to President, with Andrew Olson returning as CFO.

3Forward Guidance and Outlook

Q2 Expectations:: Anticipated core yield to remain between 12% to 12.5%.

Prepayment Guidance:: Expected to increase significantly to $350 million to $500 million in Q2, driven by M&A.

Investment Strategy:: Continued focus on disciplined underwriting and maintaining a conservative balance sheet amid market volatility.

4Bad News, Challenges, or Points of Concern

NAV Decline:: Decreased by 1.9% due to unrealized depreciation from market volatility.

Market Volatility:: Ongoing concerns related to AI disruption and geopolitical tensions affecting the broader market.

Increased Operating Expenses:: Rising costs associated with record new originations, which may pressure margins.

Credit Monitoring:: Enhanced scrutiny of portfolio due to market conditions, though credit quality remains stable.

5Notable Q&A Insights

Portfolio Performance:: Management emphasized the strength of their diversified portfolio, particularly in life sciences, which is expected to benefit from ongoing FDA developments.

Prepayment Impact:: Increased prepayments viewed positively, allowing for capital redeployment into high-quality opportunities.

Structural Changes in Underwriting:: Emphasis on tighter structures and covenants over chasing yield, reflecting a cautious approach in the current market.

AI Impact:: While AI is a concern, management noted that most M&A activity in their portfolio is not directly driven by AI trends. Overall, Hercules Capital reported a strong Q1 2026 with record financial metrics and a robust outlook, despite facing challenges from market volatility and declining NAV. The strategic focus remains on disciplined underwriting and capitalizing on favorable market conditions.